CION Ameerpet
Lung Cancer Immunotherapy · Treatment Decisions
Immunotherapy Alone or With Chemotherapy for Lung Cancer — What Actually Decides It
For patients with advanced lung cancer who are suitable for immunotherapy at all, one number drives this choice more than any other: the PD-L1 score on your biopsy report. NCCN and ESMO guidance treats that score, together with whether your tumour carries a targetable driver alteration, as the starting point for choosing immunotherapy on its own or immunotherapy given alongside chemotherapy. Eligibility is settled first — and in India a significant share of lung cancer patients are not candidates for immunotherapy in the first line.
Medically reviewed by Dr. T. Raghavender Reddy, Medical Oncologist, MBBS · DM (Medical Oncology) · MD (Radiation Oncology) · Last reviewed August 2026
- Not everyone is a candidate — A targetable EGFR or ALK alteration, active autoimmune disease or ongoing high-dose steroids can rule out immunotherapy first-line.
- The PD-L1 score is the pivot — A tumour proportion score of 50% or above opens the door to immunotherapy on its own; below that, the combination is usually preferred.
- Adding chemotherapy is about timing — It acts faster, which matters when symptoms need control within weeks. It is not a sign the immunotherapy is weaker.
- Cost clarity before you commit — We put the expected monthly cost of both approaches in writing, including scans and supportive medicines.
17+
Cancer Specialists
on Panel
on Panel
96.9%
Breast Cancer
Survival Rate*
Survival Rate*
15,000+
Patients
Treated
Treated
4.8★
Google Rating
(800+ reviews)
(800+ reviews)
Eligibility comes first
Who Is Not Eligible for Lung Cancer Immunotherapy in the First Place?
Many patients are not. If your tumour carries a targetable EGFR, ALK or ROS1 alteration, targeted tablets come first and immunotherapy is generally not used at that point. Active autoimmune disease, an organ transplant, or ongoing high-dose steroids can also rule it out. Immunotherapy is decided after the biomarker report, never before it.
Reasons immunotherapy is usually not offered first-line, whether alone or with chemotherapy:
- A targetable driver alteration — EGFR, ALK, ROS1 and several others are treated with targeted tablets first.
- Active autoimmune disease that needs ongoing immunosuppression to keep it controlled.
- Corticosteroids above a low daily dose at the time treatment would start.
- A solid organ transplant, because of the risk to the graft.
- Very poor performance status, where the burden of treatment outweighs the likely benefit.
- No biomarker report yet — without PD-L1 and mutation results this decision cannot honestly be made.
This matters more in India than a quick read of Western guidance suggests. Targetable EGFR and ALK alterations are found in a substantial share of non-squamous lung cancers here, and far more often in people who never smoked. Starting immunotherapy before that panel is back can mean missing a treatment that would have suited you better. At CION the biomarker report is reviewed by the tumour board before any first-line plan is confirmed.
The deciding factor
What Decides Immunotherapy Alone or Immunotherapy With Chemotherapy?
The PD-L1 score on your biopsy decides it more than anything else. A high score means immunotherapy on its own is a reasonable option. A low score means chemotherapy is usually added alongside it. Tumour type, how fast the disease is moving, and how well you are managing daily activities then adjust that starting point.
| PD-L1 score (TPS) | What the band means | Usual first-line approach |
|---|---|---|
| 50% or above | Half or more of the tumour cells stain for PD-L1 — the band in which single-agent immunotherapy is expected to work in a proportion of patients. | Immunotherapy alone is an accepted option. The combination is still chosen when disease is bulky or symptoms need controlling quickly. |
| 1% to 49% | Some PD-L1 is present, but not enough for immunotherapy on its own to be the default choice. | Immunotherapy with chemotherapy is usually preferred. Immunotherapy alone is reserved for patients who cannot take chemotherapy. |
| Less than 1% | Very little PD-L1 expression on the tumour cells. | Immunotherapy with chemotherapy. Immunotherapy on its own is not recommended in this band. |
| Not tested or report pending | The information the decision rests on is not available yet. | The choice waits for the report. If disease needs urgent control, chemotherapy may start while testing is completed. |
TPS = tumour proportion score, the percentage of tumour cells staining for PD-L1. Bands as used in NCCN and ESMO non-small cell lung cancer guidance. Your report may also quote a CPS score, which is calculated differently and is not used the same way in lung cancer.
What else moves the decision:
- Histology — squamous or non-squamous changes which chemotherapy partner is used, not whether immunotherapy is used.
- Performance status — the combination asks more of the body; a lower score can point towards immunotherapy alone.
- Disease burden and symptoms — when a response is needed within weeks, chemotherapy is added because it acts faster.
- Kidney function, blood counts and other illnesses — these decide whether chemotherapy can be given safely at all.
- Small cell versus non-small cell — a different rulebook applies, covered further down this page.
Is one enough?
Is Immunotherapy Alone Enough Without Chemotherapy?
For selected patients, yes. With non-small cell lung cancer, no targetable alteration, and a PD-L1 score of 50% or above, immunotherapy on its own is an accepted first-line option. It is not enough for everyone. Below that score, and when disease is bulky or moving fast, the chemotherapy partner is added deliberately.
The reasoning behind adding chemotherapy is timing, not weakness. Chemotherapy usually begins shrinking disease within a few weeks. Immunotherapy can take longer to show its effect. When someone is breathless, in pain, or losing weight quickly, that gap matters, and the combination is used to cover it. Being offered the combination is not a signal that your cancer is worse than someone else's, and being offered immunotherapy alone is not a signal that you are being given less.
It is also honest to say that in a proportion of patients, immunotherapy alone does not control the disease. That is why the first response scan is planned from the outset and why the plan is written to be changed. Immunotherapy aims to help your own immune system recognise the cancer; it does not do so in every patient, and no team can tell you in advance which group you will fall into.
12+ Centres in Hyderabad · Pick yours
CION cancer care is closer than you think.
We're never more than 30 minutes away. Same panel of specialists at every centre. Same tumour board reviews. Same NCCN protocols. Pick the closest one and call directly — or let us pick for you.
CION Ameerpet
CION Kukatpally
CION L.B. Nagar
CION Tolichowki
CION Masab Tank
CION Banjara Hills
CION Kompally
CION Balanagar
CION Siddipet
CION Sangareddy
Not sure which centre fits best? Tell us where you are — we'll suggest the closest one with the right specialists.
Help me pick the right centre
Beyond Hyderabad
35+ centres across Telangana & Andhra Pradesh
Travelling for treatment? We may have a centre right where you are.
Telangana
Andhra Pradesh
Don't see your city? Call 18002028726 — we'll find your nearest CION partner centre.
Meet the Specialists
17+ senior cancer specialists. One panel for your case.
Trained at AIIMS, Tata Memorial, and leading international centres. Combined 150+ years of experience. Every complex case is reviewed by 3+ of them — together.
Medical Oncologist
Medical Oncologist
Dr. C. Raghavendra Reddy
MBBS(Gold Medal), DNB(General Medicine), DM(Medical Oncology)(Gold Medal)
Medical Oncologist
Dr. Bharati Devi Gorantla
MBBS, MD(General Medicine), DM(Medical Oncology)(Adyar,Chennai), ECMO, MRCP SCE(UK)
Medical Oncologist
Dr. Owais Mohammed
MBBS, MD (General Medicine), DrNB (Medical Oncology), ECMO, MRCP SCE (Medical Oncology) (UK)
Medical Oncologist
Medical Oncologist
Surgical Oncologist
Dr. Muralidhar Muddusetty
MBBS (AIIMS), MS (Surgery) (AIIMS), DNB (Surgical Oncology), MRCS (Edinburgh)
Surgical Oncologist
Surgical Oncologist
Surgical Oncologist
Dr. Vinay Mamidala
MBBS, MS(General Surgery), M.Ch(Surgical Oncology), FMAS, FARIS(Ongoing)
Surgical Oncologist
Radiation Oncologist
Radiation Oncologist
Radiation Oncologist
Hematologist
Interventional Radiologist
Dr. Mohammed Imran
Surgical Oncologist
Dr. Vajja Sandeep Kumar
MBBS, MS (General Surgery), DrNB (Surgical Oncology), FALS Oncology
Surgical Oncologist
Want a specific doctor for your case? Mention them when booking.
Book Free ConsultationBook an appointment with our specialist
Share your name and number — we'll call you back within 30 minutes to schedule your consultation.
One Decision, Two Very Different Treatment Years
Bring your PD-L1 and mutation reports to a 45-minute consultation and get the reasoning, not just the prescription.
Side by side
How Do the Two Approaches Differ Day to Day?
The immunotherapy part looks the same in both. What changes is the chemotherapy phase at the start: longer day-care visits, more blood tests, and a different side-effect pattern for the first few months. After that phase ends, a combination plan usually continues as immunotherapy alone.
| What you are comparing | Immunotherapy alone | Immunotherapy with chemotherapy |
|---|---|---|
| Where it is given | Day care at a CION centre — no overnight stay | Day care at a CION centre — no overnight stay |
| Typical schedule | Every three weeks, or a longer interval on an extended schedule | Every three weeks during the chemotherapy phase, then immunotherapy alone as maintenance |
| Time in the chair | Usually under an hour once pre-medication is done | Usually several hours on chemotherapy days |
| Hair loss | Not expected from immunotherapy itself | Common with several chemotherapy partners |
| Nausea and appetite | Uncommon | Common during the chemotherapy phase, managed with anti-sickness medication |
| Blood counts | Checked before each cycle | Checked more often; low counts can delay a cycle |
| Main side-effect pattern | Immune-related — thyroid, skin, gut, liver and lung inflammation, appearing weeks to months in | Chemotherapy effects early, plus the same immune-related pattern on its own timeline |
| First response assessment | Usually around 9 to 12 weeks | Often earlier, around 6 to 9 weeks |
Response-assessment scans, including PET-CT, are coordinated for you at partner imaging centres — CION does not own the scanners, and we tell you where the scan is booked and what it will cost before you go.
Did you know?
PD-L1 is not a yes-or-no result. It is reported as a percentage of tumour cells that stain positive, the tumour proportion score. Two people can both be told they are PD-L1 positive and still be pointed towards completely different first-line plans, because one scored 60% and the other scored 5%.
The cost question
Is Immunotherapy Alone Cheaper Than Immunotherapy With Chemotherapy?
Usually a little, and rarely as much as families hope. The immunotherapy component is the largest single line in the bill, and it continues either way. Chemotherapy adds drug cost, supportive medicines and closer monitoring for the first few months. That is a real difference, but a small share of the total.
What stays the same in both plans:
- The immunotherapy infusion itself, which dominates the monthly cost in both approaches.
- Day-care charges, nursing time and review consultations.
- Response-assessment scans, coordinated at partner imaging centres.
- The immune-related side-effect monitoring that comes with any checkpoint-inhibitor treatment.
What the chemotherapy phase adds:
- The chemotherapy drugs themselves, usually for a limited number of cycles rather than indefinitely.
- Anti-sickness and supportive medication, and sometimes growth-factor support if counts drop.
- More frequent blood tests during the first few months.
- A higher chance of an unplanned visit or admission for a side effect, which is the cost families most often forget to budget for.
Three things change the total far more than this decision does: how long immunotherapy continues, whether a biosimilar version is available for the product your oncologist selects, and what your insurance, Aarogyasri, CGHS, ECHS or ESI cover allows. All cost figures for these regimens are indicative, as of August 2026, and move with brand, biosimilar availability, centre and scheme coverage. Ask for the expected monthly cost of both options in writing before you agree to either. A fuller breakdown is on our cost of immunotherapy for lung cancer in India page.
A framework, not a recommendation
What Should You Ask Before Agreeing to Either Plan?
Ask for the reasoning, not just the prescription. Six questions cover almost everything that matters here: your biomarker results, the histology, why this option over the other, what would change the plan, what each option costs, and what happens if you choose not to have immunotherapy at all.
- What is my PD-L1 score, and was a full driver-mutation panel done? If either answer is missing, the decision is not ready to be made.
- Is my cancer non-small cell or small cell? The alone-versus-combination question only applies to non-small cell disease.
- Why this option for me specifically, and not the other one? The answer should reference your score, your scans and your fitness, not general practice.
- What would make you change the plan, and when would we know? Ask for the date of the first response scan before you start.
- What is the expected monthly cost of each option, in writing? Include scans, supportive medicines and the cost of a possible admission.
- What happens if we do not use immunotherapy at all? Chemotherapy alone, targeted therapy, a clinical trial, or best supportive care are real options, and a good team will set them out rather than treat the question as defeatist.
No page can make this choice for you, and this one is not trying to. The decision belongs to you, your family and the oncologist who has seen your scans. What you are owed is the reasoning behind it, in language you can repeat at home.
Before you decide
Ask Why, Not Just What
Every immunotherapy plan at CION goes through a tumour board, and the reasoning is explained to the family in plain language.
Real Stories. Real Voices.
15,000+ patients chose CION. Hear from them directly.
These aren't paid endorsements or written reviews. These are video testimonials from real patients and families — recorded on their own phones, in their own words. Pick any one. Watch it. Then decide.
4.8★800+ Google reviews
50+video testimonials
15,000+patients treated
Read all 800+ reviews on Google
Start Your Story. Book Free Consultation.
Common questions
Immunotherapy Alone or With Chemotherapy: Your Questions Answered
What decides whether I get immunotherapy alone or immunotherapy with chemotherapy for lung cancer?
The PD-L1 score on your biopsy report is the main deciding factor, once a targetable driver alteration has been ruled out. A tumour proportion score of 50% or above makes immunotherapy on its own an accepted first-line option in NCCN and ESMO guidance for non-small cell lung cancer. Below 50%, immunotherapy combined with chemotherapy is usually preferred. Your oncologist then adjusts for how much disease there is, how quickly it is progressing, how well you are managing daily activities, and whether your kidneys, blood counts and other conditions allow chemotherapy safely.
Is single-agent immunotherapy enough on its own for lung cancer?
For a selected group it is. Patients with non-small cell lung cancer, no targetable EGFR or ALK alteration, and a PD-L1 score of 50% or above can be offered immunotherapy alone as a recognised first-line option. It is not enough for everyone. In a proportion of patients the disease does not respond, and chemotherapy is added or substituted at that point. When PD-L1 is low, or the disease is bulky and causing symptoms that need control within weeks, the combination is chosen from the start rather than held in reserve.
Is immunotherapy alone cheaper than immunotherapy with chemotherapy?
It is usually a little cheaper, but far less so than most families expect. The immunotherapy component is the largest single line in the bill and it continues in both plans. Adding chemotherapy adds the chemotherapy drugs, anti-sickness and supportive medicines, more frequent blood tests and a longer day-care visit. Those are real costs, but a small share of the total. All figures for these regimens are indicative, as of August 2026, and change with brand, biosimilar availability, centre and scheme coverage. Ask for the expected monthly cost of both plans in writing before you decide.
Why might immunotherapy not be an option for my lung cancer at all?
Immunotherapy is decided after the biomarker report, never before it. If your tumour carries a targetable EGFR, ALK or ROS1 alteration, targeted tablets are used first and immunotherapy is generally not given at that stage. Active autoimmune disease needing immunosuppression, a solid organ transplant, or ongoing corticosteroids above a low daily dose can also make it unsuitable. Very poor performance status is another reason. In India these exclusions matter more than Western guidance alone suggests, because targetable alterations are found in a substantial share of non-squamous lung cancers, especially in people who never smoked.
Does this decision apply to small cell lung cancer as well?
No. In extensive-stage small cell lung cancer, immunotherapy is added to chemotherapy rather than used on its own, and the PD-L1 score does not drive that choice the way it does in non-small cell disease. Alone versus with chemotherapy is therefore a non-small cell question. If your report says small cell, ask your oncologist to confirm the histology first, because the whole framework around it, including scan timing and how long treatment continues, is different.
Can the approach change later if the first plan does not work?
Yes. Both plans are reviewed at the first response scan, usually within the first two to three months, and again before each cycle. If immunotherapy alone is not controlling the disease, chemotherapy can be added or the plan changed. If the chemotherapy phase of a combination is complete or is not being tolerated, treatment often continues as immunotherapy alone as maintenance. At CION each of these changes goes back to the tumour board rather than being made by a single doctor.